Bicalutamide 150mg: A review of its use in the treatment of locally advanced prostate cancer

Drugs

Volumn 66, Issue 6, 2006, Pages 837-850

  Wellington, Keri ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE;

ARTHRALGIA; ASTHENIA; BACKACHE; BONE DENSITY; CASTRATION; CONSTIPATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER FUNCTION TEST; MASTALGIA; MONOTHERAPY; PHARYNGITIS; PROSTATE CANCER; RASH; REVIEW; SIDE EFFECT;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33646889289     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666060-00007     Document Type: Review

References (57)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-8
2. American Cancer Society. Cancer facts and figures 2006. Atlanta (GA): American Cancer Society, 2006
3. Boccon-Gibod L, Bertaccini A, Bono AV, et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003; 57 (3): 187-94
4. Damber JE. Decreasing mortality rates for prostate cancer: possible role of hormonal therapy? BJU Int 2004; 93 (6): 695-701
5. Aus G, Abbou CC, Bolla M, et al. European Association of Urology guidelines on prostate cancer [online]. Available from URL: http://www.uroweb. org/ [Accessed 2006 Feb 20]
6. Mason M. How should we treat patients with locally advanced prostate cancer? European Urology Supplements 2003; 2 (9): 14-22
7. Sciarra A, Cardi A, Salvatori G, et al. Which patients with prostate cancer are actually candidates for hormone therapy? Int Braz J Urol 2004; 30 (6): 455-65
8. O'Connor KM, Fitzpatrick JM. Side-effects of treatments for locally advanced prostate cancer. BJU Int 2006; 97 (1): 22-8
9. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 2005; 16 Suppl. 1: i34-6
10. National Comprehensive Cancer Network. Clinical practice guidelines in oncology v.2.2005: prostate cancer [online]. Available from URL: http://www.nccn.org [Accessed 2006 Feb 20]
11. Carswell CI, Figgitt DP. Bicalutamide: in early-stage prostate cancer. Drugs 2002; 62 (17): 2471-9
12. Klotz L, Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clin Prostate Cancer 2005 Mar; 3 (4): 215-9
13. Masiello D, Cheng S, Bubley GJ, et al. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002 Jul 19; 277 (29): 26321-6
14. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93 (9): 1177-82
15. Goa KL, Spencer CM. Bicalutamide in advanced prostate cancer: a review. Drugs Aging 1998 May; 12 (5): 401-22
16. Schellhammer P. Bicalutamide (Casodex™). Expt Opin Invest Drugs 1996 Dec; 5 (12): 1707-22
17. Vicentini C, Festuccia C, Angelucci A, et al. Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. Anticancer Res 2002 Sep-Oct; 22 (5): 2917-22
18. Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994 Oct; 41: 525-30
19. Denis L, Mahler C. Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Urology 1996 Jan; 47 Suppl. 1A: 26-8
20. Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004; 43 (13): 855-78
21. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005 Feb 1; 23 (4): 808-15
22. Sieber PR, Keiller DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004 Jun; 171 (6 Pt 1): 2272-6
23. Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004 Jul 1; 22 (13): 2546-53
24. AstraZeneca. Casodex 150mg international prescribing information [online]. Available from URL: www.casodex.net [Accessed 2005 Nov 21]
25. AstraZeneca UK Limited. Casodex 150 mg film-coated tablets. SPC from the eMC [online]. Available from URL: www.http://emc.medicines.org.uk [Accessed 2006 Feb 8]
26. See WA, McLeod D, Iversen P, et al. The bicalutamide Early Prostate Cancer Program: demography. Urol Oncol 2001; 6: 43-7
27. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002 Aug; 168: 429-35
28. Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. J Urol 2004; 172 (5 Pt 1): 1865-70
29. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97 (2): 247-54
30. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 Mar; 51: 389-96
31. Iversen P, Tyrrell CJ, Kaisary AM, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000 Nov; 164: 1579-82
32. Iversen P, Wirth MP, See WA, et al. Is the efficacy of hormonal therapy affected by lymph node status? Data from the Bicalutamide (Casodex) Early Prostate Cancer Program. Urology 2004 May; 63 (5): 928-33
33. Iversen P, Johansson J-E, Lodding P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004 Nov; 172 (5 Pt 1): 1871-6
34. See WA, Iversen P, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care significantly improves prostate specific antigen progression-free survival in patients with early, non-metastatic prostate cancer: median 5.4 years' follow-up [abstract no. 1062]. J Urol 2004; 171 (4) Suppl.: 280. Plus poster presented at the 99th Annual Meeting of the American Urological Association; 2004 May 8-13; San Francisco (CA)
35. Iversen P, Johansson J-E, Lodding P, et al. Efficacy and tolerability of bicalutamide in early non-metastatic prostate cancer: latest findings from the Scandinavian Prostatic Cancer Group Study no 6 (SPCG-6) of the Early Prostate Cancer Programme [abstract plus oral presentation]. 21st Annual Congress of the European Association of Urology; 2006 Apr 5-8; Paris
36. Wirth M, Tyrrell C, Delaere K, et al. Adjuvant therapy with bicalutamide 150mg versus standard care alone: third analysis results from trial 24 of the Early Prostate Cancer Programme. 21st Annual Congress of the European Association of Urology; 2006 Apr 5-8; Paris
37. Iversen P. The third analysis of the bicalutamide Early Prostate Cancer programme. BJU Int 2006 Mar; 97 (3): 438-9
38. Kaisary AV. Evaluating the use of early hormonal therapy patients with localised or locally advanced prostate cancer. Prostate Cancer Prostatic Dis 2005; 8 (2): 140-51
39. Abrahamsson PA. Treatment of locally advanced prostate cancer: a new role for antiandrogen monotherapy? Eur Urol 2001; 39 Suppl. 1: 22-8
40. Anderson J. Quality of life aspects of treatment options for localized and locally advanced prostate cancer. Eur Urol 2001; 40 Suppl. 2: 24-30
41. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005 Apr 1; 61 (5): 1285-90
42. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 [published erratum appears in J Clin Oncol 2004; 22 (2): 386]. J Clin Oncol 2003 Nov 1; 21 (21): 3972-8
43. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 Dec 9; 341 (24): 1781-8
44. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 Jul 13; 360 (9327): 103-8
45. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000 Jan; 163: 181-6
46. Committee on Safety of Medicines. Casodex 150mg (bicalutamide): no longer indicated for treatment of localised prostate cancer [online]. Available from URL: http://www.mhra.gov.uk [Accessed 2006 Apr 6]
47. Health Canada. Important drug safety information. [online]. Available from URL: http://www.hc-sc.gc.ca [Accessed 2006 Apr 6]
48. Wirth MP, Froehner M. The management of localized or locally advanced prostate cancer. Am J Cancer 2002; 1 (6): 387-96
49. Sternberg CN. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU Int 2006 Mar; 97 (3): 435-8
50. Kirby RS, Watson A, Newling DWW, et al. Prostate cancer and sexual function. Prostate Cancer Prostatic Dis 1998; 1 (4): 179-84
51. Di Lorenzo G, Autorino R, Perdona S, et al. Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol 2005 Dec; 6 (12): 972-9
52. Perdona S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005 May; 6 (5): 295-300
53. Saltzstein D, Sieber P, Morris T, et al. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005; 8 (1): 75-83
54. Di Lorenzo G, Perdona S, De Placido S, et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 2005 Dec; 174 (6): 2197-203
55. Fradet Y, Egerdie B, Anderson M, et al. Assessment of the optimum dose of tamoxifen for the prophylaxis of bicalutamide-associated breast events [abstract no. 186]. Can J Urol 2005; 12 (3): 2665
56. Boccardo F, Rubagotti A, Conti G, et al. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemother Pharmacol 2005; 56: 415-20
57. Moeremans K, Caekelbergh K, Annemans L. Cost-effectiveness analysis of bicalutamide (Casodex.) for adjuvant treatment of early prostate cancer. Value Health 2004 Jul; 7 (4): 472-81